{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:37:00Z","timestamp":1766180220400},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11882-008-0054-2","type":"journal-article","created":{"date-parts":[[2008,10,11]],"date-time":"2008-10-11T22:30:25Z","timestamp":1223764225000},"page":"339-347","source":"Crossref","is-referenced-by-count":22,"title":["Biologic agents in the management of inflammatory eye diseases"],"prefix":"10.1007","volume":"8","author":[{"given":"Kira","family":"Michalova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndell","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,11]]},"reference":[{"key":"54_CR1","first-page":"1078","volume":"335","author":"International Study Group for Behcet\u2019s Disease","year":"1990","unstructured":"International Study Group for Behcet\u2019s Disease: Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 1990, 335:1078\u20131080.","journal-title":"Lancet"},{"key":"54_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"P.P. Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 2001, 358:295\u2013296.","journal-title":"Lancet"},{"key":"54_CR3","first-page":"1362","volume":"31","author":"S. Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362\u20131368.","journal-title":"J Rheumatol"},{"key":"54_CR4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"P.P. Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med 2004, 140:404\u2013406.","journal-title":"Ann Intern Med"},{"key":"54_CR5","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I. Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease. Arthritis Rheum 2005, 52:2478\u20132484.","journal-title":"Arthritis Rheum"},{"key":"54_CR6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B. Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI: Adalimumab for sight threatening uveitis in Beh\u00e7et\u2019s disease. Eye 2007, 21:824\u2013825.","journal-title":"Eye"},{"key":"54_CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","volume":"66","author":"J.A.M. Laar van","year":"2007","unstructured":"van Laar JAM, Missoten T, van Daele PLA, et al.: Adalimumab, a new modality for Beh\u00e7et\u2019s disease? Ann Rheum 2007, 66:565\u2013566.","journal-title":"Ann Rheum"},{"key":"54_CR8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","volume":"45","author":"R.K. Saurenmann","year":"2006","unstructured":"Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor \u03b1 inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982\u2013989.","journal-title":"Rheumatology"},{"key":"54_CR9","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I. Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692\u20131695.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"54_CR10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B. Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Bertrand Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335\u2013339.","journal-title":"Br J Ophthalmol"},{"key":"54_CR11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I. Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423\u2013431.","journal-title":"Br J Ophthalmol"},{"key":"54_CR12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"C.M. Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DRW: Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD 52 antibody CAMPATH 1-H. Rheumatology 2003, 42:1539\u20131544.","journal-title":"Rheumatology"},{"key":"54_CR13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"R.R. Buggage","year":"2007","unstructured":"Buggage RR, Levy-Clarke G, Sen HN, et al.: A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease. Ocul Immunol Inflam 2007, 15:63\u201370.","journal-title":"Ocul Immunol Inflam"},{"key":"54_CR14","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","volume":"96","author":"R.B. Nussenblatt","year":"1999","unstructured":"Nussenblatt RB, Fortin E, Schiffman R, et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial. Proc Natl Acad Sci U S A 1999, 96:7462\u20137466.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"54_CR15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","volume":"110","author":"G.N. Papaliodis","year":"2003","unstructured":"Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786\u2013789.","journal-title":"Ophthalmology"},{"key":"54_CR16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","volume":"112","author":"R.B. Nussenblat","year":"2005","unstructured":"Nussenblat RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005, 112:764\u2013770.","journal-title":"Ophthalmology"},{"key":"54_CR17","first-page":"185","volume":"19","author":"M.W. Ziegenhagen","year":"2002","unstructured":"Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J: Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:185\u2013190.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"54_CR18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"R.P. Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Resp Crit Care Med 2006, 174:795\u2013802.","journal-title":"Am J Resp Crit Care Med"},{"key":"54_CR19","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","volume":"127","author":"J.D. Doty","year":"2005","unstructured":"Doty JD, Mazur JE, Marc A, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064\u20131071.","journal-title":"Chest"},{"key":"54_CR20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","volume":"128","author":"R.P. Baughman","year":"2005","unstructured":"Baughman RP, Lower EE, Bradley DA, et al.: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062\u20131147.","journal-title":"Chest"},{"key":"54_CR21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0037-9","volume":"25","author":"J.L. Callejas-Rubio","year":"2006","unstructured":"Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596\u2013597.","journal-title":"Clin Rheumatol"},{"key":"54_CR22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","volume":"91","author":"M. Gallagher","year":"2007","unstructured":"Gallagher M, Quinones K, Cervantes-Castaneda RE, et al.: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91:1341\u20131344.","journal-title":"Br J Ophthalmol"},{"key":"54_CR23","first-page":"1991","volume":"25","author":"R.E. Petty","year":"1998","unstructured":"Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991\u20131994.","journal-title":"J Rheumatol"},{"key":"54_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","volume":"244","author":"P.E. Carvounis","year":"2006","unstructured":"Carvounis PE, Herman DC, Cha S, Burke JP: Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006, 244:281\u2013290.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"54_CR25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A. Reiff","year":"2001","unstructured":"Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411\u20131415.","journal-title":"Arthritis Rheum"},{"key":"54_CR26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","volume":"53","author":"J.A. Smith","year":"2005","unstructured":"Smith JA, Thompson DJS, Whitcup SM, et al.: A randomized, placebo controlled, double masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18\u201323.","journal-title":"Arthritis Rheum"},{"key":"54_CR27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","volume":"48","author":"P. Quartier","year":"2003","unstructured":"Quartier P, Taupin P, Bourdeaut F, et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093\u20131101.","journal-title":"Arthritis Rheum"},{"key":"54_CR28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"D.J. Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763\u2013769.","journal-title":"N Engl J Med"},{"key":"54_CR29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P. Tynj\u00e4l\u00e4","year":"2007","unstructured":"Tynj\u00e4l\u00e4 P, Lindahl P, Honkanen V, et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548\u2013550.","journal-title":"Ann Rheum Dis"},{"key":"54_CR30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P. Kahn","year":"2006","unstructured":"Kahn P, Weis M, Imundo LF, Levy DM: Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113:860\u2013864.","journal-title":"Ophthalmology"},{"key":"54_CR31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S. Biester","year":"2007","unstructured":"Biester S, Deuter C, Michels H, et al.: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91:319\u2013324.","journal-title":"Br J Ophthalmol"},{"key":"54_CR32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"L.B. Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJA: Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149:572\u2013575.","journal-title":"J Pediatr"},{"key":"54_CR33","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/keh205","volume":"43","author":"J. Braun","year":"2004","unstructured":"Braun J, Sieper J: Biological therapies in the spondyloarthritides\u2014the current state. Rheumatology 2004, 43:1072\u20131084.","journal-title":"Rheumatology"},{"key":"54_CR34","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J. Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447\u20132451.","journal-title":"Arthritis Rheum"},{"key":"54_CR35","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","volume":"109","author":"Y. El-Shabrawi","year":"2002","unstructured":"El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342\u20132346.","journal-title":"Ophthalmology"},{"key":"54_CR36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","volume":"125","author":"L. Sobrin","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895\u2013900.","journal-title":"Arch Ophthalmol"},{"key":"54_CR37","first-page":"1377","volume":"151","author":"A.W. Rijthoven Van","year":"2007","unstructured":"Van Rijthoven AW, Jacobs JW: Seronegative spondylarthropathy: variable manifestations, common characteristics. Ned Tijdschr Geneeskd 2007, 151:1377\u20131381.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"54_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","volume":"14","author":"M. Taban","year":"2006","unstructured":"Taban M, Dupps WJ, Mandel B, Perez V: Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006, 14:145\u2013150.","journal-title":"Ocul Immunol Inflamm"},{"key":"54_CR39","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"L.L. Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248\u20133252.","journal-title":"Arthritis Rheum"},{"key":"54_CR40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"E.B. Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005, 123:903\u2013912.","journal-title":"Arch Ophthalmol"},{"key":"54_CR41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","volume":"89","author":"E.W. Lindstedt","year":"2005","unstructured":"Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533\u2013536.","journal-title":"Br J Ophthalmol"},{"key":"54_CR42","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","volume":"144","author":"S.P. Ardoin","year":"2007","unstructured":"Ardoin SP, Kredich D, Rabinovich E, et al.: Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007, 144:844\u2013849.","journal-title":"Am J Ophthalmol"},{"key":"54_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","volume":"121","author":"C.S. Foster","year":"2003","unstructured":"Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437\u2013440.","journal-title":"Arch Ophthalmol"},{"key":"54_CR44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","volume":"144","author":"J. Plskova","year":"2007","unstructured":"Plskova J, Greiner K, Forrester JV: Interferon-\u03b1 as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144:55\u201361.","journal-title":"Am J Ophthalmol"},{"key":"54_CR45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","volume":"26","author":"C.E. Deuter","year":"2006","unstructured":"Deuter CE, Koetter I, Guenaydin I, et al.: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006, 26:786\u2013791.","journal-title":"Retina"},{"key":"54_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","volume":"84","author":"A.D. Dick","year":"2000","unstructured":"Dick AD, Meyer P, James T, et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000, 84:107\u2013109.","journal-title":"Br J Ophthalmol"},{"key":"54_CR47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000103239","volume":"39","author":"C. Tappeiner","year":"2007","unstructured":"Tappeiner C, Heinz C, Specker C, Heilinghaus A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007, 39:184\u2013186.","journal-title":"Ophthalmic Res"},{"key":"54_CR48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2003.013961","volume":"63","author":"F.C. Breedveld","year":"2004","unstructured":"Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149\u2013155.","journal-title":"Ann Rheum Dis"},{"key":"54_CR49","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","volume":"45","author":"J.R. Smith","year":"2001","unstructured":"Smith JR, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001, 45:252\u2013257.","journal-title":"Arthritis Care Res"},{"key":"54_CR50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.ICL.0000092064.05514.04","volume":"30","author":"M. Hernandez-Illas","year":"2004","unstructured":"Hernandez-Illas M, Tozman E, Fulcher SFA, et al.: Recombinant human tumor necrosis factor receptor Fc fusion protein (etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens 2004, 30:2\u20135.","journal-title":"Eye Contact Lens"},{"key":"54_CR51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"C.C. Murphy","year":"2004","unstructured":"Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352\u2013356.","journal-title":"Ophthalmology"},{"key":"54_CR52","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A. Galor","year":"2006","unstructured":"Galor A, Perez VL, Hammel JP, Lowder CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317\u20132323.","journal-title":"Ophthalmology"},{"key":"54_CR53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 2005, 352:351\u2013361.","journal-title":"N Engl J Med"},{"key":"54_CR54","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","volume":"89","author":"C.M. Cheung","year":"2005","unstructured":"Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener\u2019s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.","journal-title":"Br J Ophthalmol"},{"key":"54_CR55","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","volume":"64","author":"K. Ahmadi-Simab","year":"2005","unstructured":"Ahmadi-Simab K, Lamprecht P, Nolle B, et al.: Successful treatment of refractory anterior scleritis in primary Sj\u00f6gren\u2019s syndrome with rituximab. Ann Rheum Dis 2005, 64:1087.","journal-title":"Ann Rheum Dis"},{"key":"54_CR56","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D. Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch WA, van der Loos TL, et al.: The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye 2005, 19:1286\u20131289.","journal-title":"Eye"},{"key":"54_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","volume":"24","author":"O.M. Durrani","year":"2005","unstructured":"Durrani OM, Reuser TQ, Murray PI: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24:117\u2013119.","journal-title":"Orbit"},{"key":"54_CR58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ajo.2004.06.077","volume":"138","author":"J.A. Garrity","year":"2004","unstructured":"Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925\u2013930.","journal-title":"Am J Ophthalmol"},{"key":"54_CR59","first-page":"374","volume":"32","author":"A.B. Adams","year":"2005","unstructured":"Adams AB, Kazim M, Lehman TJA: Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005, 32:374\u2013375.","journal-title":"J Rheumatol"},{"key":"54_CR60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M. Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I, et al.: Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156:33\u201340.","journal-title":"Eur J Endocrinol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-008-0054-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0054-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:42:18Z","timestamp":1559418138000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-008-0054-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s11882-008-0054-2","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}